Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride 5% acts as an osmotic diuretic. The hypertonic solution creates an osmotic gradient that draws water from the intracellular space into the extracellular compartment, increasing intravascular volume and promoting free water clearance. It also replaces sodium and chloride deficits.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
FDA-approved: Treatment of hyponatremia (symptomatic or severe), osmotic diuresis, and as a source of electrolytes.,Off-label: Cerebral edema, increased intracranial pressure, management of herniation syndromes, intraoperative fluid resuscitation in hyponatremic patients.
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion: 500-1000 m L as a single dose; rate varies based on patient status and indication.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
The terminal half-life of administered sodium and chloride is approximately 8–12 hours for excess free water elimination, reflecting renal clearance; for sodium ions, the half-life is highly variable and dependent on hydration status, renal function, and hormonal regulation (ADH, aldosterone). In anuric patients, half-life may extend to 24–48 hours.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Sodium and chloride are not metabolized; they are excreted primarily by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Sodium and chloride ions are freely filtered by the glomerulus; >90% is reabsorbed in the renal tubules under homeostatic regulation. Fractional excretion of sodium (FENa) is typically <1% in euvolemic states. Unabsorbed ions are eliminated in urine, with negligible biliary or fecal excretion.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Sodium and chloride ions are not protein bound; they exist as free ions in plasma.
Low protein binding; 0–11% bound, primarily to albumin.
Approximately 0.6–0.7 L/kg, corresponding to total body water. For sodium, the Vd approximates the extracellular fluid volume (~0.2 L/kg) because sodium is primarily extracellular; chloride distributes similarly.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% bioavailability. Oral: Variable; sodium and chloride are nearly completely absorbed (≥95%) via active transport and solvent drag in the small intestine.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Contraindicated in severe renal impairment with oliguria or anuria; use with caution and monitor fluid balance in mild to moderate impairment.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No adjustment required; monitor sodium levels in patients with ascites or cirrhosis.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion: 5-10 m L/kg/dose, administered over 2-6 hours; maximum rate 0.5-1 m Eq/kg/hour.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution due to increased risk of fluid overload and electrolyte disturbances; consider reduced infusion rates and close monitoring.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of hypernatremia and hyperosmolality, especially in patients with renal impairment or those receiving large volumes.,Central pontine myelinolysis (osmotic demyelination) if hyponatremia is corrected too rapidly.,Infusion reactions: phlebitis, extravasation, and hypervolemia.,Use with caution in patients with heart failure, renal failure, or edema.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypernatremia, hyperchloremia, hypokalemia, or hyperosmolality.,Patients with fluid overload (e.g., pulmonary edema, congestive heart failure).,Severe renal impairment with oliguria or anuria.,Concurrent use of corticosteroids or corticotropin (may increase sodium retention).
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions, but patients with hyponatremia should avoid excessive water intake and adhere to any fluid restrictions prescribed. A balanced diet with appropriate sodium intake as per medical advice is recommended. Avoid high-sodium processed foods if at risk of fluid overload.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Sodium chloride is a normal constituent of body fluids and is not teratogenic. No fetal risks have been associated with its administration at therapeutic doses in any trimester.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Sodium chloride is excreted into breast milk but is considered compatible with breastfeeding. The M/P ratio is not reported as it is a normal electrolyte.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
No specific dose adjustments are required for pregnancy; however, monitor for fluid retention and electrolyte disturbances as pregnancy alters fluid homeostasis.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Use with caution in patients with congestive heart failure, severe renal impairment, or hypernatremia. Monitor serum sodium levels frequently. Rapid infusion can cause fluid overload, especially in elderly or pediatric patients. In hyponatremia, correct sodium slowly (≤8-10 m Eq/L per 24 hours) to avoid osmotic demyelination. Hypertonic saline (3% or higher) is preferred for severe symptomatic hyponatremia; 5% is rarely used as it is more hyperosmolar. Ensure patency of IV access and assess for signs of extravasation due to hypertonic solution.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is a concentrated salt solution used to correct low sodium levels in your blood.,You may experience injection site pain or irritation; report any redness or swelling to your healthcare provider.,During treatment, you will have regular blood tests to monitor your sodium levels and kidney function.,Tell your doctor if you have a history of heart failure, kidney disease, or if you are on a low-salt diet.,Do not consume large amounts of salt in your diet unless directed by your doctor.,Seek immediate medical attention if you experience headache, nausea, confusion, or seizures, which may indicate rapid sodium correction.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 5% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride 5% acts as an osmotic diuretic. The hypertonic solution creates an osmotic gradient that draws water from the intracellular space into the extracellular compartment, increasing intravascular volume and promoting free water clearance. It also replaces sodium and chloride deficits.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 5% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 5% IN PLASTIC CONTAINER is: Intravenous infusion: 500-1000 m L as a single dose; rate varies based on patient status and indication.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 5% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 5% IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride is a normal constituent of body fluids and is not teratogenic. No fetal risks have been associated with its administration at therapeutic doses in any trimester.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.